Baxter president reports initial stock, option stakes
Baxter International executive Steven P. Wallace, President of Advanced Surgery, reported his initial holdings on a Form 3.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
Baxter International executive Steven P. Wallace, President of Advanced Surgery, reported his initial holdings on a Form 3. He directly owns 70,282 shares of common stock and holds several stock option awards covering additional shares at exercise prices between $20.37 and $74.47 with expirations from 2032 through 2036.
Insider Trade Summary
5 transactions reported
Mixed
5 txns
Insider
Wallace Steven P.
Role
President, Adv. Surgery
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Common Stock, $1 par value | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 67,972 contracts (Direct);
Common Stock, $1 par value — 70,282 shares (Direct)
Footnotes (4)
- F1. The options became exercisable in three equal annual installments beginning on June 1, 2023, the first anniversary of the grant date.
- F2. The options became exercisable in three equal annual installments beginning on March 1, 2024, the first anniversary of the grant date.
- F3. The options became exercisable in three equal annual installments beginning on March 6, 2026, the first anniversary of the grant date.
- F4. The options become exercisable in three equal annual installments beginning on March 1, 2027, the first anniversary of the grant date.
Key Figures
Direct common shares: 70,282 shares
Option grant 1: 8,918 shares at $74.47
Option grant 2: 15,352 shares at $39.06
+2 more
5 metrics
Direct common shares
70,282 shares
Directly held Baxter common stock as reported on Form 3
Option grant 1
8,918 shares at $74.47
Stock option, expires June 1, 2032
Option grant 2
15,352 shares at $39.06
Stock option, expires March 1, 2033
Option grant 3
17,840 shares at $35.44
Stock option, expires March 6, 2035
Option grant 4
25,862 shares at $20.37
Stock option, expires February 27, 2036
Key Terms
Stock Option (Right to Buy), Common Stock, $1 par value, exercisable in three equal annual installments, exercise price
4 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)" for multiple entries"
Common Stock, $1 par value financial
"underlying_security_title: "Common Stock, $1 par value""
exercisable in three equal annual installments financial
"The options became exercisable in three equal annual installments beginning on June 1, 2023"
exercise price financial
"conversion_or_exercise_price values such as "74.4700" and "20.3700""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Steven P. Wallace’s Form 3 for Baxter (BAX) report?
The Form 3 reports Steven P. Wallace’s initial ownership in Baxter. It shows directly held common stock plus multiple stock option grants with specified exercise prices and long-dated expirations, establishing his baseline equity position as President of Advanced Surgery.
What stock options are reported for Steven P. Wallace in Baxter (BAX)?
The filing lists several stock option awards, each giving rights to buy Baxter common stock at fixed prices. These options cover 8,918 shares at $74.47, 15,352 at $39.06, 17,840 at $35.44, and 25,862 at $20.37, all held directly.
When do Steven P. Wallace’s Baxter (BAX) stock options expire?
The reported Baxter stock options have staggered expiration dates. They expire on June 1, 2032; March 1, 2033; March 6, 2035; and February 27, 2036, providing a long-term window during which Wallace can choose to exercise them.
How do Steven P. Wallace’s Baxter (BAX) options vest according to the footnotes?
The footnotes state each option grant becomes exercisable in three equal annual installments. Vesting begins on the first anniversary of the respective grant dates, such as June 1, 2023 or March 1, 2024, spreading Wallace’s ability to exercise over several years.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates